JP2006503071A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006503071A5 JP2006503071A5 JP2004540151A JP2004540151A JP2006503071A5 JP 2006503071 A5 JP2006503071 A5 JP 2006503071A5 JP 2004540151 A JP2004540151 A JP 2004540151A JP 2004540151 A JP2004540151 A JP 2004540151A JP 2006503071 A5 JP2006503071 A5 JP 2006503071A5
- Authority
- JP
- Japan
- Prior art keywords
- amphetamine
- pharmaceutical composition
- sustained release
- cellulose acetate
- dextroamphetamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 38
- 238000013268 sustained release Methods 0.000 claims description 27
- 239000012730 sustained-release form Substances 0.000 claims description 27
- 239000011248 coating agent Substances 0.000 claims description 26
- 238000000576 coating method Methods 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 18
- 239000011159 matrix material Substances 0.000 claims description 14
- 238000004090 dissolution Methods 0.000 claims description 9
- 230000036470 plasma concentration Effects 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 5
- 229940047812 adderall Drugs 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 32
- 150000003839 salts Chemical class 0.000 claims 20
- KWTSXDURSIMDCE-MRVPVSSYSA-N (R)-amphetamine Chemical compound C[C@@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-MRVPVSSYSA-N 0.000 claims 18
- 229950005223 levamfetamine Drugs 0.000 claims 18
- 229940025084 amphetamine Drugs 0.000 claims 17
- 239000001856 Ethyl cellulose Substances 0.000 claims 16
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 16
- 235000019325 ethyl cellulose Nutrition 0.000 claims 16
- 229920001249 ethyl cellulose Polymers 0.000 claims 16
- 235000014113 dietary fatty acids Nutrition 0.000 claims 14
- 229930195729 fatty acid Natural products 0.000 claims 14
- 239000000194 fatty acid Substances 0.000 claims 14
- 229960000632 dexamfetamine Drugs 0.000 claims 11
- 229920002301 cellulose acetate Polymers 0.000 claims 9
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims 9
- 239000011118 polyvinyl acetate Substances 0.000 claims 9
- 229920002689 polyvinyl acetate Polymers 0.000 claims 9
- 229920008347 Cellulose acetate propionate Polymers 0.000 claims 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 8
- 150000004665 fatty acids Chemical class 0.000 claims 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 7
- 240000008042 Zea mays Species 0.000 claims 7
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims 7
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims 7
- 235000005822 corn Nutrition 0.000 claims 7
- -1 fatty acid esters Chemical class 0.000 claims 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 7
- 229920000193 polymethacrylate Polymers 0.000 claims 7
- 239000001993 wax Substances 0.000 claims 7
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 6
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 6
- 229920002494 Zein Polymers 0.000 claims 6
- 125000005233 alkylalcohol group Chemical group 0.000 claims 6
- 239000005019 zein Substances 0.000 claims 6
- 229940093612 zein Drugs 0.000 claims 6
- VHKVKWTWHZUFIA-DGOKBZBKSA-N (2s)-1-phenylpropan-2-amine;(2s,3s,4s,5r)-2,3,4,5-tetrahydroxyhexanedioic acid Chemical compound C[C@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O VHKVKWTWHZUFIA-DGOKBZBKSA-N 0.000 claims 4
- OJNSNSZTGUACNI-IBFUIWIBSA-N N[C@H](CC(O)=O)C(O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 Chemical compound N[C@H](CC(O)=O)C(O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 OJNSNSZTGUACNI-IBFUIWIBSA-N 0.000 claims 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 4
- 229940052327 amphetamine aspartate Drugs 0.000 claims 4
- PYHRZPFZZDCOPH-UHFFFAOYSA-N amphetamine sulfate Chemical compound OS(O)(=O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-UHFFFAOYSA-N 0.000 claims 4
- 229940008238 amphetamine sulfate Drugs 0.000 claims 4
- 229940052370 dextroamphetamine saccharate Drugs 0.000 claims 4
- 108060006613 prolamin Proteins 0.000 claims 4
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 229940119751 dextroamphetamine sulfate Drugs 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000002459 sustained effect Effects 0.000 claims 2
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 229920006218 cellulose propionate Polymers 0.000 claims 1
- 229920003176 water-insoluble polymer Polymers 0.000 claims 1
- 239000011324 bead Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960002048 guanfacine Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41279902P | 2002-09-24 | 2002-09-24 | |
| US10/353,073 US6913768B2 (en) | 2002-09-24 | 2003-01-29 | Sustained release delivery of amphetamine salts |
| PCT/US2003/029757 WO2004028509A1 (en) | 2002-09-24 | 2003-09-24 | Sustained released delivery of amphetamine salts |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006503071A JP2006503071A (ja) | 2006-01-26 |
| JP2006503071A5 true JP2006503071A5 (enExample) | 2006-10-26 |
Family
ID=31996998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004540151A Pending JP2006503071A (ja) | 2002-09-24 | 2003-09-24 | アンフェタミン塩の持続放出型送達 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US6913768B2 (enExample) |
| EP (1) | EP1542660B1 (enExample) |
| JP (1) | JP2006503071A (enExample) |
| KR (1) | KR20050084589A (enExample) |
| CN (1) | CN1684668B (enExample) |
| AP (1) | AP2030A (enExample) |
| AT (1) | ATE495731T1 (enExample) |
| AU (1) | AU2003272619B2 (enExample) |
| BR (1) | BR0314486A (enExample) |
| CA (1) | CA2499546C (enExample) |
| CR (1) | CR7766A (enExample) |
| CY (1) | CY1112335T1 (enExample) |
| DE (1) | DE60335807D1 (enExample) |
| DK (1) | DK1542660T3 (enExample) |
| EA (1) | EA018082B1 (enExample) |
| EC (1) | ECSP055702A (enExample) |
| ES (1) | ES2360046T3 (enExample) |
| HR (1) | HRP20050356A2 (enExample) |
| IL (1) | IL167470A (enExample) |
| IS (1) | IS2814B (enExample) |
| MA (1) | MA27469A1 (enExample) |
| MX (1) | MXPA05003129A (enExample) |
| NO (1) | NO336938B1 (enExample) |
| NZ (1) | NZ539216A (enExample) |
| OA (1) | OA13075A (enExample) |
| PL (1) | PL375991A1 (enExample) |
| SI (1) | SI1542660T1 (enExample) |
| WO (1) | WO2004028509A1 (enExample) |
| ZA (1) | ZA200502406B (enExample) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6322819B1 (en) | 1998-10-21 | 2001-11-27 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
| US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
| US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
| US8394813B2 (en) | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
| US7169752B2 (en) | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
| US20060014697A1 (en) | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
| US7105486B2 (en) * | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
| US7659253B2 (en) * | 2002-02-22 | 2010-02-09 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| US7700561B2 (en) * | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| WO2004071501A1 (en) * | 2003-02-10 | 2004-08-26 | Shire Biochem Inc. | Enantiomeric amphetamine compositions for the treatment of adhd |
| WO2004091483A2 (en) | 2003-04-07 | 2004-10-28 | Shire Laboratories, Inc. | Once daily formulations of tetracyclines |
| AU2004251647B2 (en) | 2003-05-29 | 2010-01-14 | Takeda Pharmaceutical Company Limited | Abuse resistant amphetamine compounds |
| DK1575565T3 (da) * | 2003-08-08 | 2010-04-12 | Biovail Lab Int Srl | Tablet med modificeret frigivelse af bupropion-hydrochlorid |
| US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| AU2005309601A1 (en) | 2004-11-23 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising a sustained release coating or matrix and an NMDA receptor antagonist, method for administration such NMDA antagonist to a subject |
| EP1845968A2 (en) | 2004-11-24 | 2007-10-24 | Neuromolecular Pharmaceuticals, Inc | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease |
| US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
| AU2006232896A1 (en) * | 2005-04-06 | 2006-10-12 | Mallinckrodt Inc. | Matrix-based pulse release pharmaceutical formulation |
| EP1874282B1 (en) | 2005-04-06 | 2010-09-15 | Adamas Pharmaceuticals, Inc. | Methods and compositions for treatment of cns disorders |
| DK2018160T3 (da) | 2006-03-16 | 2012-02-06 | Tris Pharma Inc | Modificeret depotformuleringer indeholdende lægemiddel-ionbytterharpikskomplekser |
| CA2649360A1 (en) * | 2006-04-10 | 2007-10-25 | Shire Llc | Mono and di-substituted oxycodone compounds and compositions |
| US20070253927A1 (en) * | 2006-04-13 | 2007-11-01 | Gwenaelle Jegou | Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator |
| JP2009533459A (ja) * | 2006-04-14 | 2009-09-17 | シャイア エルエルシー | 共有結合する化合物の鎮痛作用の増強と、有害な副作用の減衰と、前記化合物の乱用の予防とのための組成物及び方法 |
| MX2008014455A (es) * | 2006-05-12 | 2008-11-27 | Shire Llc | Sistema de suministro de farmaco de dosis controlada. |
| US8846100B2 (en) | 2006-05-12 | 2014-09-30 | Shire Llc | Controlled dose drug delivery system |
| KR100774613B1 (ko) * | 2006-05-26 | 2007-11-12 | 한국화학연구원 | 수불용성 고분자로 이루어진 서방형 약물 전달체 |
| CA2671200A1 (en) * | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophilic abuse deterrent delivery system |
| US20080207668A1 (en) * | 2006-10-06 | 2008-08-28 | New River Pharmaceuticals Inc. | Pharmaceutical compositions of hydromorphone for prevention of overdose or abuse |
| US20080090771A1 (en) * | 2006-10-06 | 2008-04-17 | Shire Llc | Abuse-resistant hydrocodone compounds, compositions and methods of using the same |
| PL2124556T3 (pl) | 2006-10-09 | 2015-02-27 | Charleston Laboratories Inc | Kompozycje farmaceutyczne |
| US20100104621A1 (en) * | 2007-02-21 | 2010-04-29 | Connected Health Systems, Llc | Treating adhd and other diseases involving inflammation |
| US20080268047A1 (en) * | 2007-04-24 | 2008-10-30 | Xavier University Of Louisiana | Controlled Release Multiple Layer Coatings |
| CA3066426A1 (en) | 2008-01-09 | 2009-07-16 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
| CA2717456A1 (en) * | 2008-03-05 | 2009-09-11 | Panacea Biotec Limited | Modified release pharmaceutical compositions comprising mycophenolate and processes thereof |
| US20100003322A1 (en) * | 2008-07-03 | 2010-01-07 | Lai Felix S | Enteric coated hydrophobic matrix formulation |
| CA2767576C (en) | 2009-07-08 | 2020-03-10 | Charleston Laboratories Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
| GB201002612D0 (en) * | 2010-02-16 | 2010-03-31 | Jagotec Ag | Improvements in or relating to organic compounds |
| WO2011133980A1 (en) | 2010-04-23 | 2011-10-27 | Subhash Desai | Therapeutic formulation for reduced drug side effects |
| US8927010B2 (en) | 2011-03-23 | 2015-01-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US10905652B2 (en) * | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9498447B2 (en) * | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9119809B2 (en) * | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| EP4316488A3 (en) * | 2011-03-23 | 2024-02-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods and compositions for treatment of attention deficit disorder |
| US11241391B2 (en) * | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9603809B2 (en) * | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
| US8916588B2 (en) * | 2011-03-23 | 2014-12-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
| US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
| EP2726066B1 (en) | 2011-06-28 | 2021-03-31 | Neos Therapeutics, LP | Dosage forms of amphetamine for oral administration |
| EP2768481A4 (en) | 2011-10-21 | 2015-07-08 | Subhash Desai | COMPOSITIONS TO REDUCE SIDE EFFECTS |
| CA2880456A1 (en) | 2012-08-15 | 2014-02-20 | Tris Pharma, Inc. | Methylphenidate extended release chewable tablet |
| EP3530268B1 (en) | 2012-10-09 | 2021-12-15 | Attentive Therapeutics, Inc. | Therapeutic treatment |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| MX2018008021A (es) | 2015-12-30 | 2018-11-09 | Adamas Pharmaceuticals Inc | Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones. |
| CA3055170A1 (en) | 2016-03-04 | 2017-09-08 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11000498B2 (en) | 2016-07-22 | 2021-05-11 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| MX2020002078A (es) | 2017-08-24 | 2020-09-21 | Adamas Pharma Llc | Composiciones de amantadina, preparaciones de estas y métodos de uso. |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US10213393B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság | Composition and method for treating neurological disease |
| US20190247331A1 (en) | 2018-02-15 | 2019-08-15 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
| US10213394B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
| EP3930702A1 (en) | 2019-03-01 | 2022-01-05 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| JP2022529353A (ja) | 2019-04-17 | 2022-06-21 | コンパス パスファインダー リミテッド | 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法 |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB768512A (en) | 1954-08-16 | 1957-02-20 | Smith Kline & French Internat | Improvements in or relating to pharmaceutical tablets |
| US4049791A (en) * | 1974-06-21 | 1977-09-20 | Delco Chemical Company, Inc. | Prolonged acting appetite suppressant and anti-obesity compositions containing amphetamine adipate, dextroamphetamine adipate, amphetamine sulfate and dextroamphetamine sulfate as the active agents |
| FR2470599A1 (fr) | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
| US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US4917899A (en) | 1983-12-22 | 1990-04-17 | Elan Corporation Plc | Controlled absorption diltiazem formulation |
| US4894240A (en) | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
| IE56999B1 (en) | 1983-12-22 | 1992-03-11 | Elan Corp Plc | Pharmaceutical formulation |
| US5002776A (en) | 1983-12-22 | 1991-03-26 | Elan Corporation, Plc | Controlled absorption diltiazem formulations |
| US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
| EP0227814A1 (en) | 1985-07-02 | 1987-07-08 | The Upjohn Company | Therapeutic formulations with bimodal release characteristics |
| GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
| DE3678644D1 (de) | 1985-08-16 | 1991-05-16 | Procter & Gamble | Wirkstoffpartikel mit sowohl kontinuierlicher als auch schneller freisetzung. |
| JPS62103012A (ja) | 1985-10-23 | 1987-05-13 | Eisai Co Ltd | 多重顆粒 |
| DE3684446D1 (de) | 1985-12-28 | 1992-04-23 | Sumitomo Pharma | Arzneimittel mit verzoegerter stossweiser freisetzung. |
| US4723958A (en) | 1986-05-23 | 1988-02-09 | Merck & Co., Inc. | Pulsatile drug delivery system |
| DE3712095A1 (de) | 1987-04-10 | 1988-10-20 | Lentia Gmbh | Bindemittelfreies granulat mit verzoegerter wirkstoffabgabe |
| DE3827214A1 (de) | 1988-08-11 | 1990-02-15 | Roehm Gmbh | Retardierte arzneiform und verfahren zu ihrer herstellung |
| US5275819A (en) | 1989-02-06 | 1994-01-04 | Amer Particle Technologies Inc. | Drug loaded pollen grains with an outer coating for pulsed delivery |
| GB2230442B (en) | 1989-02-16 | 1992-11-25 | Nat Res Dev | Controlled release device |
| FI920856A0 (fi) | 1989-08-28 | 1992-02-26 | Pharmaceutical Delivery System | Bioeroderbar polymerer foer kontrollerad frigoerelse av terapeutiska aemnen. |
| JPH0674206B2 (ja) | 1989-12-28 | 1994-09-21 | 田辺製薬株式会社 | 放出制御型製剤およびその製法 |
| US5229131A (en) | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
| US5156850A (en) | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
| US5232705A (en) | 1990-08-31 | 1993-08-03 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
| IE70328B1 (en) | 1991-01-30 | 1996-11-13 | Alza Corp | Osmotic device for delayed delivery of agent |
| US5226902A (en) | 1991-07-30 | 1993-07-13 | University Of Utah | Pulsatile drug delivery device using stimuli sensitive hydrogel |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5308348A (en) | 1992-02-18 | 1994-05-03 | Alza Corporation | Delivery devices with pulsatile effect |
| US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
| EP0653935B1 (en) | 1992-08-05 | 2002-05-08 | F.H. FAULDING & CO. LIMITED | Pelletised pharmaceutical composition |
| US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
| JP2916978B2 (ja) | 1993-08-25 | 1999-07-05 | エスエス製薬株式会社 | 放出開始制御型製剤 |
| US5395626A (en) | 1994-03-23 | 1995-03-07 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
| US5582855A (en) | 1994-07-01 | 1996-12-10 | Fuisz Technologies Ltd. | Flash flow formed solloid delivery systems |
| FR2723536A1 (fr) | 1994-08-11 | 1996-02-16 | Seth Pawan | Composition permettant une liberation selective d'un principe actif |
| US5731314A (en) | 1995-01-06 | 1998-03-24 | Bencherif; Merouane | Pharamceutical compositions for prevention and treatment of tourette's syndrome |
| JPH11509227A (ja) | 1995-07-14 | 1999-08-17 | カイロサイエンス・リミテッド | ｄ−トレオ−メチルフェニデートの治療的使用 |
| US5908850A (en) | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
| US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US5922736A (en) | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
| HRP970493A2 (en) | 1996-09-23 | 1998-08-31 | Wienman E. Phlips | Oral delayed immediate release medical formulation and method for preparing the same |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US5885616A (en) | 1997-08-18 | 1999-03-23 | Impax Pharmaceuticals, Inc. | Sustained release drug delivery system suitable for oral administration |
| US6210705B1 (en) | 1997-12-15 | 2001-04-03 | Noven Pharmaceuticals, Nc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
| US6372254B1 (en) | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
| US5945123A (en) | 1998-04-02 | 1999-08-31 | K-V Pharmaceutical Company | Maximizing effectiveness of substances used to improve health and well being |
| US6322819B1 (en) | 1998-10-21 | 2001-11-27 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
| KR20070051953A (ko) | 1998-11-02 | 2007-05-18 | 엘란 코포레이션, 피엘씨 | 다입자 변형 방출 조성물 |
| US6673367B1 (en) | 1998-12-17 | 2004-01-06 | Euro-Celtique, S.A. | Controlled/modified release oral methylphenidate formulations |
| US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
| EP1165054A4 (en) | 1999-04-06 | 2005-02-09 | Pharmaquest Ltd | PHARMACEUTICAL DOSAGE FORM FOR INTERMITTENT DELIVERY OF METHYLPHENIDATE |
| US6384020B1 (en) * | 1999-07-14 | 2002-05-07 | Shire Laboratories, Inc. | Rapid immediate release oral dosage form |
| CA2477004C (en) * | 2002-02-22 | 2011-05-10 | Thomas Piccariello | Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
| WO2004071501A1 (en) * | 2003-02-10 | 2004-08-26 | Shire Biochem Inc. | Enantiomeric amphetamine compositions for the treatment of adhd |
| US8846100B2 (en) * | 2006-05-12 | 2014-09-30 | Shire Llc | Controlled dose drug delivery system |
-
2003
- 2003-01-29 US US10/353,073 patent/US6913768B2/en not_active Expired - Lifetime
- 2003-09-24 HR HR20050356A patent/HRP20050356A2/xx not_active Application Discontinuation
- 2003-09-24 MX MXPA05003129A patent/MXPA05003129A/es active IP Right Grant
- 2003-09-24 CN CN038227029A patent/CN1684668B/zh not_active Expired - Fee Related
- 2003-09-24 CA CA002499546A patent/CA2499546C/en not_active Expired - Lifetime
- 2003-09-24 OA OA1200500086A patent/OA13075A/en unknown
- 2003-09-24 WO PCT/US2003/029757 patent/WO2004028509A1/en not_active Ceased
- 2003-09-24 AU AU2003272619A patent/AU2003272619B2/en not_active Ceased
- 2003-09-24 NZ NZ539216A patent/NZ539216A/en not_active IP Right Cessation
- 2003-09-24 DE DE60335807T patent/DE60335807D1/de not_active Expired - Lifetime
- 2003-09-24 ZA ZA200502406A patent/ZA200502406B/xx unknown
- 2003-09-24 PL PL03375991A patent/PL375991A1/xx not_active Application Discontinuation
- 2003-09-24 AT AT03754811T patent/ATE495731T1/de active
- 2003-09-24 JP JP2004540151A patent/JP2006503071A/ja active Pending
- 2003-09-24 EA EA200500530A patent/EA018082B1/ru not_active IP Right Cessation
- 2003-09-24 DK DK03754811.2T patent/DK1542660T3/da active
- 2003-09-24 KR KR1020057005127A patent/KR20050084589A/ko not_active Withdrawn
- 2003-09-24 AP AP2005003275A patent/AP2030A/xx active
- 2003-09-24 SI SI200331985T patent/SI1542660T1/sl unknown
- 2003-09-24 ES ES03754811T patent/ES2360046T3/es not_active Expired - Lifetime
- 2003-09-24 BR BR0314486-0A patent/BR0314486A/pt not_active Application Discontinuation
- 2003-09-24 EP EP03754811A patent/EP1542660B1/en not_active Expired - Lifetime
-
2005
- 2005-01-07 US US11/030,174 patent/US20050158384A1/en not_active Abandoned
- 2005-03-16 IL IL167470A patent/IL167470A/en active IP Right Grant
- 2005-03-18 CR CR7766A patent/CR7766A/es unknown
- 2005-03-21 MA MA28168A patent/MA27469A1/fr unknown
- 2005-03-23 EC EC2005005702A patent/ECSP055702A/es unknown
- 2005-04-22 IS IS7818A patent/IS2814B/is unknown
- 2005-04-22 NO NO20051986A patent/NO336938B1/no not_active IP Right Cessation
-
2011
- 2011-04-15 CY CY20111100379T patent/CY1112335T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006503071A5 (enExample) | ||
| CA2724533C (en) | Stabilized atypical antipsychotic formulation | |
| US8062666B2 (en) | Extended release compositions comprising as active compound venlafaxine hydrochloride | |
| CA2124012C (fr) | Formulation de diltiazem a liberation prolongee | |
| US9248119B2 (en) | Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors | |
| MXPA05001077A (es) | Formulacion farmaceutica oral bajo forma de una pluralidad de microcapsulas que permiten la liberacion prolongada de principio(s) activo(s) poco soluble(s). | |
| DE60224194T2 (de) | Arzneizusammensetzungen enthaltend terbinafin und deren verwendung | |
| HU197839B (en) | Process for producing metoprolol containing pharmaceutical compositions | |
| JP2012107048A (ja) | 時限拍動性薬物送達システム | |
| US20090311317A1 (en) | Modified release tolterodine formulations | |
| KR20210121071A (ko) | 피부용 조성물 | |
| EP2726064A1 (en) | Controlled release oral dosage form comprising oxycodone | |
| KR20150119069A (ko) | 2종의 펠릿을 다수 포함하는 다중미립자 제약 조성물 | |
| US8105627B2 (en) | Extended release venlafaxine tablet formulation | |
| CA2645940A1 (en) | Controlled release formulation of tolterodine | |
| US20090136550A1 (en) | Modified release formulations of diltiazem | |
| AU2018286535B2 (en) | Delayed sustained release pharmaceutical compositions | |
| US20150086626A1 (en) | Stable dosage forms of skeletal muscle relaxants with extended release coating | |
| TR201801650T1 (tr) | Kontrollü salim propi̇veri̇n formülasyonlari | |
| US11918590B2 (en) | Stable extended release pharmaceutical composition of clozapine | |
| BR112019024708B1 (pt) | Composição farmacêutica de liberação prolongada retardada e seu uso no tratamento de adhd | |
| EP3474825A1 (en) | Sustained release formulation comprising tizanidine | |
| IL159780A (en) | Venlfaxine tablet for prolonged release | |
| HRP920590A2 (en) | New pharmaceutical preparation |